Good afternoon. Welcome to the 2026 Annual Meeting of Stockholders of ArriVent BioPharma, Inc. I'm Jim Kastenmayer, General Counsel and Secretary of the company, and it is my pleasure to welcome you. It is 12:00 P.M. Eastern Time on Thursday, June 18, 2026. In accordance with the notice of the meeting, I call to order the 2026 Annual Meeting of Stockholders of ArriVent BioPharma, Inc.
We have chosen to have this meeting virtually in order to improve our stockholders' access to this meeting. It is our intention to conduct this meeting in accordance with the agenda, which is available in the Meeting Materials section of the meeting website. There will be an opportunity for questions about the two proposals as they are presented. You will also note that under Item nine in the agenda, an opportunity is provided at the end of the meeting for general questions and discussion .
Please hider to the rules of conduct, also available on the meeting materials section of the meeting website and asking question. If we are unable to answer your question during the meeting, we wilI follow with you afterwards. Before proceeding to the business of meeting, I would like to introduce our CEO and Chairman, Bing Yao.
A warm welcome, thanks to all of you for joining us today. I would like to introduce our directors who have joined us today. John Hohneker, Chris Nolet, Merdad Parsey, Kristine Peterson. The directors who are candidates for re-election at today's meetings are James Haley, John Hohneker, and Merdad Parsey. Also present today are Alexander Raymond of PricewaterhouseCoopers LLP, the company's auditors. John Rudy and Nishant Dharia of Mintz, the company's outside counsel. Beth Vanderbeck of the Caredio Group, who is serving as the inspector of the election for this meeting. If questions arise during the discussion period that these individuals should appropriately address, they will be glad to respond. Mr. Kastenmayer will serve as Secretary of this meeting. Mr. Kastenmayer, please proceed with the meeting.
This meeting is held pursuant to a printed notice mailed on or about April 28, 2026, to each stockholder of record as of April 21st, 2026, who is entitled to vote. A count of shares present immediately prior to the meeting indicated that 33,418,793 shares of the company's voting capital stock were present in person or by proxy. This is 72.07% of the outstanding voting stock of the company. I hereby declare a quorum present at the meeting. On behalf of the board of directors of the company, I would like to express our appreciation to all stockholders who returned their proxies. I would also like to point out that most of you who returned proxies authorized the persons named in the proxy to vote for the election of management's nominees for director.
Those of you who would like to vote today may do so by clicking on the button on your screen entitled Vote Here. The first matter to be acted upon by the stockholders is the election of three directors, each to serve until the annual meeting to be held in 2029 and until his or her successor has been elected and qualified. Dr. Yao just introduced the nominees and additional information about them is in the proxy statement. I hereby declare them duly nominated.
The company has not received timely notice of any other nominations. I therefore declare the nominations closed. If you have questions regarding this proposal, please submit those questions now. The next matter being submitted to stockholders for action is the ratification of the appointment by the board of directors of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2026 fiscal year.
If you have questions regarding this proposal, please submit those questions now. The stockholders who are voting at the meeting on these proposals should now vote. After voting has been completed, votes will be counted. Please vote on each proposal using the links provided in the webcast. We have completed. I hereby declare the polls closed for all proposals. We will prepare preliminary results of the voting at this time. We have completed a preliminary count of the ballots. We will now report the preliminary results for each of the two proposals. For the first proposal, the requisite number of shares has been voted for the election of the three directors named in the proxy statement for terms expiring on the date of the annual meeting in 2029.
For the second proposal, 33,411,777 shares, being more than the majority of the shares cast affirmatively or negatively for this proposal, have been voted in favor of. 829 shares have been voted against, and 6,191 shares have been abstained from ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2026 fiscal year. I hereby declare that the nominees for director have been duly elected and that the appointment of PricewaterhouseCoopers LLP has been duly ratified. After the final tabulation has been completed, it should be placed with the minutes of this meeting. I will now turn back to Bing Yao for the conclusion of the meeting.
This concludes the formal portion of our meeting. I would again like to express my sincere appreciation to the stockholders who attended the meeting and have voted, as well as those who submitted their proxies. Although the meeting is now formally adjourned, we are available to discuss questions which any of you may have. If you have a question, please type your question into the box labeled Ask a Question and click Submit. We have not received any questions. Thank you for your attention and the continuing support of ArriVent BioPharma, Inc. We appreciate your attendance. Thank you